Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.

Sonpavde GP, Maughan BL, McGregor BA, Wei XX, Kilbridge KL, Lee RJ, Yu EY, Schweizer MT, Montgomery RB, Cheng HH, Hsieh AC, Jain R, Grewal JS, Pico-Navarro C, Gafoor Z, Perschy T, Grivas P.

Open source

DOI: 10.1007/s00262-022-03274-6
Published: 2022-08-23
Container: Cancer Immunol Immunother
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00262-022-03274-6,
  title = {Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.},
  author = {Sonpavde GP and  Maughan BL and  McGregor BA and  Wei XX and  Kilbridge KL and  Lee RJ and  Yu EY and  Schweizer MT and  Montgomery RB and  Cheng HH and  Hsieh AC and  Jain R and  Grewal JS and  Pico-Navarro C and  Gafoor Z and  Perschy T and  Grivas P.},
  year = {2023},
  journal = {Cancer Immunol Immunother},
  doi = {10.1007/s00262-022-03274-6},
  url = {https://doi.org/10.1007/s00262-022-03274-6}
}

RIS

TY  - JOUR
TI  - Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
AU  - Sonpavde GP
AU  -  Maughan BL
AU  -  McGregor BA
AU  -  Wei XX
AU  -  Kilbridge KL
AU  -  Lee RJ
AU  -  Yu EY
AU  -  Schweizer MT
AU  -  Montgomery RB
AU  -  Cheng HH
AU  -  Hsieh AC
AU  -  Jain R
AU  -  Grewal JS
AU  -  Pico-Navarro C
AU  -  Gafoor Z
AU  -  Perschy T
AU  -  Grivas P.
PY  - 2023
JO  - Cancer Immunol Immunother
DO  - 10.1007/s00262-022-03274-6
UR  - https://doi.org/10.1007/s00262-022-03274-6
ER  -

APA

GP, S., BL, M., BA, M., XX, W., KL, K., RJ, L., EY, Y., MT, S., RB, M., HH, C., AC, H., R, J., JS, G., C, P., Z, G., T, P., & P., G. (2023). Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-022-03274-6

Source records

europe-pmc · retrieved 2026-09-25T11:30:24.549Z